Sorry, you need to enable JavaScript to visit this website.

STELARA® Dosing - Psoriasis | STELARA® (ustekinumab)
  1. Considering STELARA®
  2. STELARA® Dosing

STELARA® Dosing

4 Doses a Year, After 2 Starter Doses

Watch this video to learn about a patient’s experience with STELARA®.

Plaque Psoriasis Dosing

First 52 weeks of therapy

This is dosing information for adults. Find STELARA® dosing information for adolescents.

stelara

6doses

Once every 12 weeks (after 2 starter doses at weeks 0 and 4)

STELARA® is a prescription medicine used to treat adults and children 12 years and older with moderate or severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).

Blocks IL-12 and IL-23 proteins involved in inflammatory immune responses.

humira

27doses

Once every other week (starting 1 week after the initial dose)

HUMIRA® is a prescription medicine used to treat adults with moderate to severe chronic plaque psoriasis who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

Blocks TNF-alpha proteins, involved in inflammatory and immune responses

cosentyx

34doses

Once every four weeks (after 5 starter doses at weeks 0, 1, 2, 3, 4). There are two injections per dose.

COSENTYX® is a prescription medication used to treat adults 18 years and older with moderate to severe plaque psoriasis that involves large areas or many areas of the body, and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment with ultraviolet or UV light, alone or with systemic therapy).

Blocks IL-17A proteins, involved in inflammatory and immune responses

enbrel

64doses

Once every week (after twice-weekly doses for the first three months)

ENBREL® is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Blocks TNF-alpha & beta proteins involved in inflammatory and immune responses

See how the dosing for STELARA® compares to an oral systemic therapy for the treatment of plaque psoriasis during the first 52 weeks of therapy.

OTEZLA®* (apremilast)

otzela_729_doses

Twice daily after starter dose (dosing milligrams vary during first five days of treatment). Blocks phosphodiesterase 4 (PDE4) enzyme involved in inflammatory and immune responses.

OTEZLA® is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

*Indicated trademarks are registered trademarks of their respective owners.

‡In medical studies, twice-weekly dosing for ENBREL® was also shown to be effective in the first 12 weeks.

^Based on the recommended 300-mg dose. 150 mg may be acceptable for some patients.

Of all the plaque psoriasis biologic medications, STELARA® has the fewest yearly doses. With only 4 doses a year after 2 starter doses, you have a full 12 weeks between doses.

STELARA® is a 45 mg or 90 mg injection given under the skin, as directed by your doctor. To start, you’ll get doses at weeks 0, 4, and then every 12 weeks after that. Your doctor can administer it, or you (or a caregiver) can inject at your home after proper training. Ask your doctor about which is the right choice for you.

If your doctor decides that you or a caregiver may give your injections at home, you should receive training on the right way to prepare and inject STELARA®. Do not try to inject yourself until you or your caregiver has been properly trained by a healthcare provider.

MORE ON STELARA® FOR ADOLESCENTS

Please read the Instructions for Use and Medication Guide before using STELARA®.

While the factors represented in the above chart are important, there are additional considerations for selecting treatment. Please talk to your doctor about treatment options and what might be right for you.

The above chart is not intended to compare the safety and effectiveness of these treatments. Please refer to each product’s full Prescribing Information for recommended dosing and administration.